Business Context and Reporting Period
Company: Biomerica, Inc. (BMRA)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: February 28, 2026 (Nine months ended February 28, 2026)
Business Overview: Biomerica is a global biomedical technology company developing diagnostic and therapeutic products, primarily focusing on gastrointestinal diseases (e.g., inFoods® IBS) and point-of-care testing. The company operates as a single segment with manufacturing facilities in the U.S. and Mexico.
Key Financial Metrics
| Metric | Three Months Ended Feb 28, 2026 | Nine Months Ended Feb 28, 2026 | Nine Months Ended Feb 28, 2025 |
|---|---|---|---|
| Net Sales | $987,000 | $3,578,000 | $4,562,000 |
| Gross Profit (Loss) | $(44,000) | $433,000 | $742,000 |
| Gross Margin | -4.5% | 12.1% | 16.3% |
| Net Loss | $(1,312,000) | $(2,630,000) | $(3,429,000) |
| Diluted EPS | $(0.44) | $(0.92) | $(1.47) |
| Cash and Equivalents (End of Period) | $1,336,000 | $1,336,000 | $3,058,000 |
| Working Capital | $2,562,000 | $2,562,000 | $3,135,000 |
| Total Liabilities | $1,561,000 | $1,561,000 | $1,840,000 |
Note: The nine-month net loss includes a one-time, non-recurring benefit of approximately $1,100,000 from the Employee Retention Credit (ERC).
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 12% in the quarter and 22% in the nine-month period compared to the prior year. The decline was driven primarily by a 48% drop in contract manufacturing revenue (due to project completion) and a 24% decrease in over-the-counter sales.
- Gross Margin Compression: The company reported a gross loss of $(44,000) in the quarter, compared to a gross profit of $19,000 in the prior year quarter. For the nine months, gross margin contracted from 16.3% to 12.1% due to product mix shifts and lower sales volume.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 6% in the quarter and 3% in the nine-month period, largely due to restructuring costs and regulatory expenses related to the commercialization of inFoods® IBS. R&D expenses decreased 18% in the quarter and 24% in the nine-month period as key projects (hp+detect™) transitioned to commercialization.
- Liquidity Reduction: Cash and cash equivalents decreased by approximately $1.06 million during the nine-month period, primarily due to operating cash outflows of $2.51 million, partially offset by $1.46 million in financing proceeds from an At-The-Market (ATM) offering.
Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months. Current cash reserves are deemed insufficient to fund operations without additional financing or significant revenue growth.
- Financing Activities: The company raised approximately $1.46 million in net proceeds during the nine months ended February 28, 2026, via the sale of 414,633 shares under its 2024 ATM Offering. Management is actively pursuing additional debt or equity financing.
- Unusual Item (ERC): The nine-month financial results include a $1.1 million non-recurring gain from the Employee Retention Credit (ERC). Excluding this item, the net loss would have been significantly higher.
- Product Commercialization: The company is in the early stages of commercializing inFoods® IBS and hp+detect™. While a Medicare reimbursement rate of $300 was established for inFoods® IBS effective January 1, 2026, coverage and utilization are not guaranteed. The company received its first commercial order for hp+detect™ in the UK market.
- Executive Departure: On April 10, 2026, Gary Lu notified the Board of his resignation as Chief Financial Officer, effective April 14, 2026. The resignation was not due to any disagreement with the company.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.34 million cash balance against the stated operating burn rate and the timeline for securing additional capital.
- Revenue Concentration: Review the dependency on key customers (one customer accounted for 36% of nine-month sales) and the impact of international trade policies/tariffs on supply chains.
- Product Adoption: Monitor the actual uptake of inFoods® IBS following the Medicare reimbursement rate announcement and the commercial performance of hp+detect™ in Europe.
- Cost Structure: Assess the sustainability of SG&A expenses relative to the declining revenue base and the effectiveness of recent cost-cutting measures.
- Leadership Transition: Confirm the appointment of a permanent replacement for the departing CFO and the status of internal controls during the transition.